نتایج جستجو برای: stimulant immunomodulators
تعداد نتایج: 7978 فیلتر نتایج به سال:
Immunomodulators were tested for their ability to stimulate proliferation and biologic activity of ameboid microglia. Only the colony-stimulating factors (CSFs), multipotential-CSF (multi-CSF) and granulocyte/macrophage-CSF (GM-CSF), were potent mitogens for microglia. Other immunomodulators, including interleukin-1, interleukin-2, interferon gamma, tumor necrosis factor, or granulocyte-CSF (G-...
BACKGROUND Although many clinical trials have been conducted in treatments of Crohn's disease (CD), whether the trial results were representative of daily practice needs to be supported by studies conducted in real-world settings. AIM This study aims to identify how CD is treated and what are the clinical effectiveness and safety of the pharmaceutical therapies of CD in real-world settings. ...
OBJECTIVES The objective of this study was to examine factors that are associated with aggression that is responsive versus refractory to individualized optimization of stimulant monotherapy among children with attention-deficit/hyperactivity disorder (ADHD). METHODS Children who were aged 6 to 13 years and had ADHD, either oppositional defiant disorder or conduct disorder, significant aggres...
OBJECTIVE To evaluate the response rate to vaccination in different treatment groups (nonimmunosuppressants and immunosuppressants). DATA SOURCES We completed an online systematic search using PubMed to identify all articles published in English between January 1990 and December 2013 assessing the effect of the response rate to vaccination in different treatment groups (with and without immun...
Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn's disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn's, effect of immunomodulators on LoR, and secondarily the effect of infliximab on gro...
BACKGROUND Recent studies report an increased risk of non-melanoma skin cancer (NMSC) in immunosuppressed patients with inflammatory bowel disease (IBD). Concurrently, paediatric IBD incidence is rising, with more patients now exposed to immunomodulators from a younger age. OBJECTIVES To investigate NMSC incidence and to examine the risk associated with immunomodulators in the development of ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید